At Digital ILC 2020, EASL is launching a policy paper with its accompanying lay summary, to inform politicians, policymakers, and the general population about the two leading causes of liver disease in Europe: non-alcoholic fatty liver disease (NAFLD) and alcohol-related…
24 August 2020 Share your best #EASLshare and win free registrations and more for ILC 2021. EASL is encouraging Digital ILC 2020 delegates to take part in the first ever EASL Share competition. Delegates are invited to enter something creative,…
Six months into the COVID-19 pandemic, an article has been published to provide guidance for physicians involved in the care of patients with chronic liver disease. 5 August 2020 – Geneva, Switzerland: This newly published review serves as an update,…
Professional societies play a major role in medicine and science. These societies tend to be large, with well-developed administrative structures. An additional model, however, is based on small groups of experts who meet regularly in an egalitarian model, to discuss…
It is with great sadness that EASL announces the passing of Prof. Roger Williams, a pioneer in liver disease and an inspiration to the world of hepatology. We send our sincere condolences to his family. His legacy spanning for nearly…
Every year, the World Hepatitis Day brings the world together to focus on the theme of raising awareness about the global burden of viral hepatitis (inflammation of the liver), and to advocate for real change. EASL calls on the global…
The curative potential of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have transformed hepatology in recent years. However, the challenge of identifying more people living with HCV remains, and further progress is needed with other forms of viral…
Researchers at EF Clif identify three different clinical courses for the first time, in patients with acute decompensated cirrhosis without acute-on-chronic liver failure (ACLF). July 14, 2020 – A clinical study led by the European Foundation for the Study of…
ClarivateTM Analytics released the 2020 update of its Journal Citation Reports©, including the much anticipated 2019 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2019 impact factor of 20.582, up from the 2018…
Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet in Sweden published in the Journal of Hepatology. The risk of…